Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies

NCT05665530 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT05665530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies
Lead sponsor
Prelude Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
September 12, 2023
Completion date
January 21, 2026
Enrollment
86 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), aggressive b-cell non-hodgkin's lymphoma (nhl), chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll), chronic myelomonocytic leukemia (cmml), diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), marginal zone lymphoma, mds/myeloproliferative neoplasm (mpn) overlap syndrome, myelodysplastic syndrome (mds), myeloid malignancies, richter's syndrome, t-cell lymphoma